CRPC with docetaxel chemotherapy-resistant patient-derived organoids was established pursuant to the method as described previously [51 (link),52 (link)]. The organoids were cultured with the advanced DMEM/F12 supplemented with 125 ng/ml rhR-spondin-1 (STEMCELL Technologies, 78213.1), 100 ng/ml rhNoggin (R&D Systems, 6057-NG-025), 1 ng/ml rhFGF (R&D Systems, 233-FB-025), rhFGF-10 (R&D Systems, 345-FG-025), 50 ng/ml (Meilunbio, China, MB8218-1), 1×N21 (R&D Systems, AR008), 10 μM Y-27632 (Abcam, Ab120129), 0.5 μM A83-01 (Beyotime Biotechnology, SF7917), 1:100 primocin (Invivogen, ant-pm-1), 10 μM SB202190 (Beyotime Biotechnology, SC0380), 10 mM Nicotinamide (Beyotime Biotechnology, S1761), and 1.25 mM N-acetylcysteine (Selleck, S1623), and the medium was changed every 2 to 3 days. Lentiviral transduction of AZGP1P2 shRNA and shRNA control was conducted according to the method as previously described [53 (link)]. The proliferation of organoids treated with 20 nM docetaxel was assessed by CCK-8 assay on the fifth day, and organoids were photographed using light microscopy. Three independent experiments were performed.
A83 01
Manufactured by Beyotime
Sourced in China
A83-01 is a small-molecule inhibitor designed for research purposes. It functions as a selective inhibitor of the TGF-beta type I receptor ALK5, preventing the activation of the TGF-beta signaling pathway. The product is intended for use in experimental studies involving cell culture and in vitro analysis.
Automatically generated - may contain errors
Lab products found in correlation
Rhr spondin 1, by STEMCELL (2 mentions)
Mb8218 1, by R&D Systems (2 mentions)
Ant pm 1, by Beyotime (2 mentions)
Nicotinamide, by Beyotime (2 mentions)
Rhnoggin, by R&D Systems (2 mentions)
Rhfgf, by R&D Systems (2 mentions)
Rhfgf 10, by R&D Systems (2 mentions)
Sb202190, by Beyotime (2 mentions)
Y 27632, by Abcam (2 mentions)
2 protocols using a83 01
1
Chemotherapy-resistant Prostate Cancer Organoid Culture
2
Chemotherapy-resistant Prostate Cancer Organoid Culture
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
CRPC with docetaxel chemotherapy-resistant patient-derived organoids was established pursuant to the method as described previously [51 (link),52 (link)]. The organoids were cultured with the advanced DMEM/F12 supplemented with 125 ng/ml rhR-spondin-1 (STEMCELL Technologies, 78213.1), 100 ng/ml rhNoggin (R&D Systems, 6057-NG-025), 1 ng/ml rhFGF (R&D Systems, 233-FB-025), rhFGF-10 (R&D Systems, 345-FG-025), 50 ng/ml (Meilunbio, China, MB8218-1), 1×N21 (R&D Systems, AR008), 10 μM Y-27632 (Abcam, Ab120129), 0.5 μM A83-01 (Beyotime Biotechnology, SF7917), 1:100 primocin (Invivogen, ant-pm-1), 10 μM SB202190 (Beyotime Biotechnology, SC0380), 10 mM Nicotinamide (Beyotime Biotechnology, S1761), and 1.25 mM N-acetylcysteine (Selleck, S1623), and the medium was changed every 2 to 3 days. Lentiviral transduction of AZGP1P2 shRNA and shRNA control was conducted according to the method as previously described [53 (link)]. The proliferation of organoids treated with 20 nM docetaxel was assessed by CCK-8 assay on the fifth day, and organoids were photographed using light microscopy. Three independent experiments were performed.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!